-
.
- Seagen Inc SGEN(* ) reported a Q4 EPS loss of $( 0.80 ), far better than the agreement of $( 1.05) as well as $( 0.95) a year back, as well as earnings of $528.15 million defeating the agreement of $480.15 million. .(* )The business anticipates 2023 earnings of $2.14-$ 2.24 billion contrasted to the agreement of $2.3 billion.
- Raymond James
- .(* )The approaching prospective increased authorization of Padcev in 1L cis-ineligible individuals (PDUFA 4/21/23) will certainly work as a springboard right into the topline information of EV-302 later on in the year. .
- .(* )RBC Resources Markets
- .
- states the boost in R&D investing vs. agreement is significant. The expert suched as monitoring’s tone on the chances for purchasing the very early pipe as well as continues to be at Outperform with a target rate of $179 (from $177). .
- anticipates Adcetris as well as Padcev to be crucial sales vehicle drivers in 2023, with Adcetris United States sales possibly going beyond $1 billion in 2023, while Tukysa remains to deal with affordable headwinds in bust cancer cells. .
- composes that Seagen is getting in a catalyst-rich duration, as well as the expert is most passionate concerning the prospective Padcev authorization in treatment-naïve urothelial cancer, which can possibly renew development for the franchise business. .
- SGEN shares are up 12.9% at $160.41 on the last check Thursday. .
.
updated the score to Solid Buy as well as increased the rate target to $175 from $155.
Information from HER2CLIMB-02 can broaden the Tukysa tag as well as offer professional as well as mechanistic understanding right into the combinability of Tukysa as well as ADCs.
increased its rate target to $155 from $145 with an Outperform score. The expert composes that pipe prioritization paves the way to ongoing financial investment in crucial areas as well as reveals the visibility of a progressing pipe, highlighted by significant (as well as revitalizing) monitoring excitement.
BMO Resources
Guggenheim
William Blair
Cost Activity:
© 2023 Benzinga.com. Benzinga does not offer financial investment recommendations. All legal rights booked.
